⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ESPR
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
globenewswire.com
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
ESPR
Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
globenewswire.com
REGN
AMGN
ESPR
ARWR
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
globenewswire.com
ESPR
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
ESPR
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
globenewswire.com
ESPR
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
globenewswire.com
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
ESPR
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
ESPR